Halozyme suffers setback as FDA halts PhII cancer program for delivery safety concerns; Alkermes unleashes PhIII data for long-lasting Abilify version;

> Halozyme ($HALO) suffered a blow as the FDA halted its pancreatic cancer drug delivery system trial over safety concerns. The company voluntarily pulled back on its Phase II study late last week. Article | More from FierceBiotech

> Alkermes ($ALKS) finished its Phase III schizophrenia study for a long-lasting version of Abilify. The delivery method should help the company move into the drug market alone, whereas in the past it has partnered with Big Pharma to develop new products. Story

> Researchers at the University of Liverpool have developed nanoparticles that they say can increase the stability of HIV drugs. More

> Celsion ($CLSN) presented at the International Symposium on Therapeutic Ultrasound data supporting its ThermoDox heat-activated liposomal encapsulation of doxorubicin, which uses high intensity focused ultrasound to deliver the cancer drug. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.